Avantor Inc. (NYSE:AVTR) Q2 2024 Earnings Conference Call July 26, 2024 8:00 AM ET Company Participants Christina Jones - VP, IR Michael Stubblefield - President & CEO Brent Jones - EVP & CFO Conference Call Participants Vijay Kumar - Evercore ISI Tycho Peterson - Jefferies Douglas Schenkel - Wolfe Research Daniel Brennan - TD Cowen Rachel Vatnsdal - JPMorgan Michael Ryskin - Bank of America Jack Meehan - Nephron Research Matthew Sykes - Goldman Sachs Conor McNamara - RBC Capital Markets Luke Sergott - Barc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ━━━━━━━━━ FORM 10-Q ━━━━━━━━━ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-38912 Avantor, Inc. (Exact name of registrant as specified in its charter) Delaware 82-2758923 (Stat ...

Avantor, Inc. (AVTR) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.70%. A quarter ago, it was expected that this company would post earnings of $0.20 per share when it actually produced earnings of $0.22, delivering a surprise of 10%.Over the last four quarters, the company has su ...

Exhibit 99.1 Avantor® Reports Second Quarter 2024 Results • Net sales of $1.70 billion, decrease of 2.4%; organic decline of 2.0% • Net income of $93 million; Adjusted EBITDA of $306 million • Diluted GAAP EPS of $0.14; adjusted EPS of $0.25 • Operating cash flow of $281 million; free cash flow of $235 million RADNOR, Pa. – July 26, 2024 – Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, toda ...

Net sales of $1.70 billion, decrease of 2.4%; organic decline of 2.0%Net income of $93 million; Adjusted EBITDA of $306 millionDiluted GAAP EPS of $0.14; adjusted EPS of $0.25Operating cash flow of $281 million; free cash flow of $235 millionRADNOR, Pa., July 26, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarte ...

NEW YORK, July 23, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Avantor Inc. (NYSE:AVTR) will replace QuidelOrtho Corp. (NASD:QDEL) in the S&P MidCap 400, and QuidelOrtho will replace Hibbett Inc. (NASD:HIBB) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, July 26. JD Sports Fashion Plc (XLON: JD) is acquiring Hibbett in a deal expected to close soon pending final closing conditions. Schneider National In ...

Avantor, Inc. (AVTR) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 26. On ...

Avantor, Inc. (AVTR) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism led by solid first-quarter 2024 results and operational workflow also looks promising. However, headwinds resulting from the loss of a significant number of customers and forex volatility are major downsides.Over the past year, this Zacks Rank #3 (Hold) stock has rallied 0.9% compared with the 4% rise of the industry and 27.1% growth of the S&P 500.The renowned provider of mission-cr ...

Company Developments - Avantor, Inc. has launched two innovative products, J.T.Baker Cell Lysis Solution and J.T.Baker Endonuclease, aimed at improving the gene therapy harvest process, enhancing efficiency, and reducing environmental impact [1][2] - The J.T.Baker Cell Lysis Solution is an eco-friendly alternative to Octoxynol-9, designed to be biodegradable and exhibit low ecotoxicity, aligning with global sustainability goals and REACH regulations [2] - The combination of J.T.Baker Cell Lysis Solution and J.T.Baker Endonuclease streamlines the harvest process by effectively removing impurities and reducing aggregation, thus enhancing productivity and maintaining the quality of viral particles [3] Industry Insights - The global gene therapy market is projected to grow from an estimated $10.47 billion to $52.40 billion by 2033, reflecting a compound annual growth rate (CAGR) of 19.6% [4] - Facility expansion for cell and gene therapies is a key driver of market growth, with increased investments in production capacity from in-house facilities and CDMOs [4] Recent Leadership Changes - Avantor appointed Corey Walker as president of Laboratory Solutions, leveraging his industry knowledge and familiarity with the organization to lead the business effectively [5] Stock Performance - Avantor's shares have declined by 9% year-to-date, contrasting with a 3.6% rise in the industry and a 15% increase in the S&P 500 during the same period [6]

Innovative Solutions Optimize the Harvest Process in Gene Therapy Manufacturing Sustainably and at ScaleRADNOR, Pa., July 1, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the launch of two innovative products that together sustainably optimize the gene therapy harvest process: J.T.Baker® Cell Lysis Solution and J.T.Baker® Endonuclease."These products ...